In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.
We compared the in vitro activity of gemifloxacin, a new quinolone antibiotic, to the activities of levofloxacin, moxifloxacin, trovafloxacin, erythromycin, and doxycycline against 20 isolates of Chlamydia pneumoniae. Gemifloxacin was the most active quinolone tested, with a MIC at which 90% of the isolates are inhibited and a minimal bactericidal concentration at which 90% of strains tested are killed of 0.25 microg/ml, but this activity was less than those of doxycycline and erythromycin.
Roblin
P M
PM
Division of Infectious Diseases, Department of Pediatrics, Health Science Center at Brooklyn, State University of New York, Brooklyn, New York 11203, USA.
Reznik
T
T
Kutlin
A
A
Hammerschlag
M R
MR
D000890:Anti-Infective Agents / Q000494:pharmacology*; D002690:Chlamydia Infections / Q000382:microbiology; D016993:Chlamydophila pneumoniae / Q000187:drug effects*; D024841:Fluoroquinolones; D000077735:Gemifloxacin; D006801:Humans; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000494:pharmacology*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D000077735:Gemifloxacin